EP1504026A4 - Therapeutische polypeptide, diese codierende nukleinsäuren und verwendungsverfahren - Google Patents

Therapeutische polypeptide, diese codierende nukleinsäuren und verwendungsverfahren

Info

Publication number
EP1504026A4
EP1504026A4 EP02794126A EP02794126A EP1504026A4 EP 1504026 A4 EP1504026 A4 EP 1504026A4 EP 02794126 A EP02794126 A EP 02794126A EP 02794126 A EP02794126 A EP 02794126A EP 1504026 A4 EP1504026 A4 EP 1504026A4
Authority
EP
European Patent Office
Prior art keywords
encodings
methods
same
nucleic acids
therapeutic polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02794126A
Other languages
English (en)
French (fr)
Other versions
EP1504026A2 (de
Inventor
John P Ii Alsobrook
David W Anderson
Ferenc L Boldog
Catherine E Burgess
Rajeev A Chillakuru
Shlomit R Edinger
Valerie L Gerlach
Linda Gorman
Bonnie E Gould-Rothberg
Xiaojia Guo
Michael E Jeffers
Weizhen Ji
Li Li
Uriel M Malyankar
Charles E Miller
Ryan Murphey
Meera Patturajan
John A Peyman
Luca Rastelli
Suresh G Shenoy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CuraGen Corp
Original Assignee
CuraGen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/309,290 external-priority patent/US20040023241A1/en
Application filed by CuraGen Corp filed Critical CuraGen Corp
Publication of EP1504026A2 publication Critical patent/EP1504026A2/de
Publication of EP1504026A4 publication Critical patent/EP1504026A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
EP02794126A 2001-12-05 2002-12-03 Therapeutische polypeptide, diese codierende nukleinsäuren und verwendungsverfahren Withdrawn EP1504026A4 (de)

Applications Claiming Priority (39)

Application Number Priority Date Filing Date Title
US309290 1994-09-20
US33660001P 2001-12-05 2001-12-05
US336600P 2001-12-05
US33828501P 2001-12-07 2001-12-07
US338285P 2001-12-07
US34134601P 2001-12-12 2001-12-12
US341346P 2001-12-12
US34147701P 2001-12-17 2001-12-17
US34154001P 2001-12-17 2001-12-17
US341540P 2001-12-17
US341477P 2001-12-17
US34259201P 2001-12-20 2001-12-20
US342592P 2001-12-20
US34429701P 2001-12-27 2001-12-27
US344297P 2001-12-27
US34490301P 2001-12-31 2001-12-31
US344903P 2001-12-31
US37328802P 2002-04-17 2002-04-17
US373288P 2002-04-17
US38098102P 2002-05-15 2002-05-15
US380981P 2002-05-15
US38149502P 2002-05-17 2002-05-17
US381495P 2002-05-17
US38374402P 2002-05-28 2002-05-28
US38353402P 2002-05-28 2002-05-28
US383744P 2002-05-28
US383534P 2002-05-28
US38382902P 2002-05-29 2002-05-29
US38402402P 2002-05-29 2002-05-29
US384024P 2002-05-29
US383829P 2002-05-29
US40178802P 2002-08-07 2002-08-07
US401788P 2002-08-07
US40635302P 2002-08-26 2002-08-26
US406353P 2002-08-26
US42275602P 2002-10-31 2002-10-31
US422756P 2002-10-31
US10/309,290 US20040023241A1 (en) 2001-12-05 2002-12-02 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
PCT/US2002/038594 WO2003050245A2 (en) 2001-12-05 2002-12-03 Therapeutic polypeptides, nucleic acids encoding same, and methods of use

Publications (2)

Publication Number Publication Date
EP1504026A2 EP1504026A2 (de) 2005-02-09
EP1504026A4 true EP1504026A4 (de) 2005-12-21

Family

ID=32303940

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02794126A Withdrawn EP1504026A4 (de) 2001-12-05 2002-12-03 Therapeutische polypeptide, diese codierende nukleinsäuren und verwendungsverfahren

Country Status (5)

Country Link
EP (1) EP1504026A4 (de)
JP (1) JP2006507793A (de)
AU (1) AU2002359579A1 (de)
CA (1) CA2467721A1 (de)
WO (1) WO2003050245A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252267B2 (en) 2005-03-30 2012-08-28 Sagres Discovery, Inc. DKKL-1 splice product modulators for cancer diagnosis and therapy
JPWO2008093827A1 (ja) * 2007-02-01 2010-05-20 財団法人大阪産業振興機構 中枢神経障害治療剤及び中枢神経障害の治療方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999007740A2 (en) * 1997-08-06 1999-02-18 Zymogenetics, Inc. Lipocalin homologs
WO2001059155A2 (en) * 2000-02-11 2001-08-16 Pharma Pacific Pty. Ltd. Interferon-alpha induced genes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999007740A2 (en) * 1997-08-06 1999-02-18 Zymogenetics, Inc. Lipocalin homologs
WO2001059155A2 (en) * 2000-02-11 2001-08-16 Pharma Pacific Pty. Ltd. Interferon-alpha induced genes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 14 January 1992 (1992-01-14), "Homo sapiens mRNA for von Ebner's gland protein", XP002335191, retrieved from EBI accession no. EM_PRO:HSVEGP Database accession no. HSVEGP *

Also Published As

Publication number Publication date
AU2002359579A1 (en) 2003-06-23
CA2467721A1 (en) 2003-06-19
WO2003050245A3 (en) 2004-12-16
EP1504026A2 (de) 2005-02-09
JP2006507793A (ja) 2006-03-09
WO2003050245A2 (en) 2003-06-19
WO2003050245A8 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
WO2003023008A8 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1576169A4 (de) Therapeutische polypeptide, diese codierende nukleinsäuren und verwendungsverfahren
EP1487864A4 (de) Therapeutische polypeptide, diese codierende nukleinsäuren und verwendungsverfahren
AU2002356534A8 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1446419A4 (de) Therapeutische polypeptide, für diese codierende nukleinsäuren und anwendungsverfahren
EP1401858A4 (de) Therapeutische polypeptide, nukleinsäuren, die für diese codieren, und verfahren zur anwendung
EP1432726A4 (de) Therapeutische polypeptide, nukleinsäuren, die für diese kodieren, und anwendungsverfahren
AU2003217956A8 (en) Therapeutic polypeptides, nucleic acids encoding same and methods of use
EP1539985A4 (de) Therapeutische polypeptide, diese codierende nukleinsäuren sowie verwendungsverfahren
EP1532238A4 (de) Therapeutische polypeptide, diese codierende nukleinsäuren und verwendungsverfahren
EP1443913A4 (de) Therapeutische polypeptide, diese codierende nukleinsäuren sowie verwendungsverfahren
EP1399537A4 (de) Therapeutische polypeptide, diese codierende nukleinsäuren und verwendungsverfahren
EP1549671A4 (de) Therapeutische polypeptide, diese kodierende nukleinsaüre und verwendungsverfahren
AU2002309646A1 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
EP1504026A4 (de) Therapeutische polypeptide, diese codierende nukleinsäuren und verwendungsverfahren
AU2002365216A8 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
IL161765A0 (en) P85-alpha nucleic acids, polypeptides and related methods
AU2003304034A8 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003060149A9 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU2003270424A8 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU2002360485A8 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU2002322405A1 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1513864A4 (de) Therapeutische polypeptide, diese codierende nukleinsäuren und verwendungsverfahren
EP1539807A4 (de) Therapeutische polypeptide, für diese kodierende nukleinsäuren und anwendungsverfahren
AU2002303232A1 (en) Novel human proteins, polynucleotides encoding them and methods of using the same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040701

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

R17D Deferred search report published (corrected)

Effective date: 20041216

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07K 14/81 B

Ipc: 7C 07K 14/47 B

Ipc: 7C 07K 1/00 B

Ipc: 7C 07K 14/435 A

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CURAGEN CORPORATION

A4 Supplementary search report drawn up and despatched

Effective date: 20051104

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060124